Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...

Sorghum is an increasingly important crop for animal and human nutrition, especially in arid and semi-arid regions, due to ...

Global Parkinson’s disease cases are projected to more than double to 25.2 million by 2050, driven largely by aging ...

In a series of three recent studies, a team led by CSIC researcher at CRAG Ana I. Caño-Delgado has made significant progress ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

A comprehensive atlas maps DNA methylation across 39 human cell types, revealing a complex landscape of epigenetic regulation.

Check about porn addiction symptoms, how it affects your mind, and its impact on relationships, time, finances, and overall ...

KOCHI: An expert committee formed by the Kerala government to study the issues faced by Fair Price Shop (FPS) dealers has proposed significant changes to the st ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as ...